6B0V

Crystal Structure of small molecule ARS-107 covalently bound to K-Ras G12C

6B0V の概要

• エントリーDOI: 10.2210/pdb6b0v/pdb
• 分子名称: GTPase KRas, CALCIUM ION, 1-[3-(4-{[(4,5-dichloro-2-hydroxyphenyl)amino]acetyl}piperazin-1-yl)azetidin-1-yl]propan-1-one, ... (5 entities in total)
• 機能のキーワード: small gtpase domain, covalent inhibitor bound, switch ii pocket, gdp bound, signaling protein
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 40582.91

構造登録者

Hansen, R.,Peters, U.,Babbar, A.,Chen, Y.,Feng, J.,Janes, M.R.,Li, L.-S.,Ren, P.,Liu, Y.,Zarrinkar, P.P. (登録日: 2017-09-15, 公開日: 2018-05-16, 最終更新日: 2024-11-13)

主引用文献

Hansen, R.,Peters, U.,Babbar, A.,Chen, Y.,Feng, J.,Janes, M.R.,Li, L.S.,Ren, P.,Liu, Y.,Zarrinkar, P.P.
The reactivity-driven biochemical mechanism of covalent KRASG12Cinhibitors.
Nat. Struct. Mol. Biol., 25:454-462, 2018

PubMed Abstract: Activating mutations in KRAS are among the most common tumor driver mutations. Until recently, KRAS had been considered undruggable with small molecules; the discovery of the covalent KRAS inhibitors ARS-853 and ARS-1620 has demonstrated that it is feasible to inhibit KRAS with high potency in cells and animals. Although the biological activity of these inhibitors has been described, the biochemical mechanism of how the compounds achieve potent inhibition remained incompletely understood. We now show that the activity of ARS-853 and ARS-1620 is primarily driven by KRAS-mediated catalysis of the chemical reaction with Cys12 in human KRAS, while the reversible binding affinity is weak, in the hundreds of micromolar or higher range. The mechanism resolves how an induced, shallow and dynamic pocket not expected to support high-affinity binding of small molecules can nevertheless be targeted with potent inhibitors and may be applicable to other targets conventionally considered undruggable.

PubMed: 29760531
DOI: 10.1038/s41594-018-0061-5

実験手法

X-RAY DIFFRACTION (1.29 Å)